|
Investigating GLP-1 Injury Cases
Ankin Law is investigating claims from people who suffered serious injuries after taking GLP-1 drugs for weight loss or diabetes, including Ozempic, Wegovy, Mounjaro, and Zepbound. These weekly injections are now among the most widely used drugs in the country. In late 2025, about one in eight American adults said they were taking one.
As of November 2, 2026, more than 4,000 lawsuits over stomach and bowel injuries were pending against the drugs’ makers, Novo Nordisk and Eli Lilly, gathered before a federal judge in Philadelphia. A separate group of 278 lawsuits claims the drugs caused NAION, sudden vision loss or blindness in one eye. On November 9, 2026, the U.S. Food and Drug Administration ordered the label of every GLP-1 drug to warn of a possible higher risk of NAION.
The people suing say the makers failed to warn patients and doctors of the drugs’ dangers. Reported injuries include gastroparesis, in which the stomach stops emptying normally, blocked intestines, gallbladder disease, and pancreatitis, which the drug labels warn can be fatal. By 2023, the FDA’s reporting system held 33 reports of blocked intestines in people taking semaglutide, including two deaths. A 2023 study in JAMA found that people using GLP-1 drugs for weight loss had about nine times the risk of pancreatitis and four times the risk of bowel obstruction, compared with people using another weight-loss drug.
If you or someone you love lost vision, suffered a severe stomach or bowel injury, or had another serious complication after taking a GLP-1 drug, call Ankin Law at 312.600.0000 for a Free Case Review.
Learn more
|